Abstract:Objective: To investigate the preliminary applicability of Prostate Imaging Reporting and Data System version 2 (PI-RADS v2) score in the condition of 3.0T multi-parametric magnetic resonance imaging (Mp-MRI) combined with clinical classic indicators for the diagnosis of prostate cancer (PCa). Methods: The clinical and MRI materials of 247 patients of suspicious prostate disease treated in Second Affiliated Hospital of Soochow University from June 2015 to November 2016 were analyzed retrospectively, including 110 cases with PCa and 137 cases without cancer.All cases underwent the high-resolution axial T(2)-weighted imaging (T(2)WI), diffusion weighted imaging (DWI) and dynamic contrast enhancement-magnetic resonance imaging (DCE-MRI) and were confirmed pathologically by puncture biopsies.The Mp-MRI materials of all cases were scored according to PI-RADS v2.The prostate volume and prostate specific antigen (PSA) density (PSAD) value were calculated according to the formulas.The univariate and multivariate analysis were performed for the observed indicators (age, prostate volume, PSA, PSAD and PI-RADS v2 score) to determine the independent predictors for PCa.Then, a Logistic regression model (combined prediction model) was established by the independent predictors for combined diagnosis of PCa.The receiver operating characteristic curve (ROC) curve analysis was performed to get the sensitivity and specificity of each independent predictor and the model to diagnose PCa.The differences of AUC values of each independent predictor and the model were compared with each other to evaluate the diagnostic performance for PCa. Results: The differences in the age, prostate volume, PSA, PSAD and the PI-RADS v2 score between patients with PCa and non-cancer group were all statistically significant (t=2.870, Z=-4.230, -7.787, -9.477, -10.826, all P<0.05). The PSAD and PI-RADS v2 score were independent predictors for PCa (OR=3.331, 10.546, both P<0.05). The Logistic regression combined prediction model by PI-RADS v2 score and PSAD to forecast PCa was Logit(P)=-5.097+ 2.309×PSAD+ 1.214×PI-RADS v2 score.The area under the curve (AUC) of ROC in the combined model (0.911) was higher than that in the PI-RADS v2 score (0.886) and PSAD (0.851) and the differences were all statistically significant (Z=2.416, 2.716, both P<0.05); but the difference in the AUC value between PI-RADS v2 score and PSAD was not statistically significant (Z=1.191, P=0.234). The diagnostic sensitivity of PSAD, PI-RADS v2 score and the model were: 0.891, 0.782 and 0.855, respectively; the specificity were 0.449, 0.912 and 0.847, respectively on their positive thresholds (0.15 μg·L(-1)·ml(-1,) 4 and -0.82). Conclusion: PI-RADS v2 score combined with PSAD in diagnosing PCa is superior to the single application of them and it can lead to high diagnostic sensitivity and specificity for PCa.

Values of multiparametric and biparametric MRI in diagnosing clinically significant prostate cancer: a multivariate analysis

MRI combined with PSA density in detecting clinically significant prostate cancer in patients with PSA serum levels of 4∼10ng/mL: Biparametric versus multiparametric MRI.

MRI Based Radiomics Compared With the PI-RADS V2.1 in the Prediction of Clinically Significant Prostate Cancer: Biparametric vs Multiparametric MRI

Evaluation of Multiparametric Magnetic Resonance Imaging in Detection and Prediction of Prostate Cancer.

Multiparametric MRI radiomics in prostate cancer for predicting Ki-67 expression and Gleason score: a multicenter retrospective study

Can the Combination of Biparametric Magnetic Resonance Imaging and PSA‐related Indicators Predict the Prostate Biopsy Outcome?

Diagnostic Performance of Multiparametric MRI Parameters for Gleason Score and Cellularity Metrics of Prostate Cancer in Different Zones: a Quantitative Comparison

The value of multiparametric MRI examination using 1.5T and 3.0T with PI-RADS (version 2) in the qualitative diagnosis of clinically significant prostate cancer

Biparametric versus multiparametric MRI for the detection of clinically significant prostate cancer in a diverse, multiethnic population

The Efficiency of Multiparametric Magnetic Resonance Imaging (mpmri) Using PI-RADS Version 2 in the Diagnosis of Clinically Significant Prostate Cancer

The value of prostate specific antigen density in the detection of prostate cancer by the multi-parametric MRI

Evaluation of clinically significant prostate cancer using biparametric magnetic resonance imaging: An evolving concept

Biparametric prostate MRI and clinical indicators predict clinically significant prostate cancer in men with "gray zone" PSA levels

The value of multiparametric MRI and transrectal ultrasound fusion guided biopsy in the detection of clinical significant prostate cancer

Biparametric vs. Multiparametric MRI in the Detection of Cancer in Transperineal Targeted-Biopsy-Proven Peripheral Prostate Cancer Lesions Classified as PI-RADS Score 3 or 3+1: The Added Value of ADC Quantification

Evaluation of multiparametric MRI in predicting seminal vesicle invasion of prostate cancer

Accuracy of Multiparametric Magnetic Resonance Imaging for Diagnosing Prostate Cancer: a Systematic Review and Meta-Analysis.

Biparametric versus multiparametric MRI in the diagnosis of prostate cancer

[Application of Artificial Intelligence Combined with Multi-Parametric MRI in the Early Diagnosis of Prostate Cancer].

Is Dynamic Contrast Enhancement Still Necessary in Multiparametric Magnetic Resonance for Diagnosis of Prostate Cancer: a Systematic Review and Meta-Analysis

[Preliminary Applicability Evaluation of Prostate Imaging Reporting and Data System Version 2 Diagnostic Score in 3.0T Multi-Parameters Magnetic Resonance Imaging Combined with Prostate Specific Antigen Density for Prostate Cancer].